← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 607개
CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART19.1 (MB-CART19.1)

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory · Melanoma Stage III

#MelanomaStageIII#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 7상태 ACTIVE
CGTBiologicStephan Grupp MD PhDPhase 2

CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD22

#CD22#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 6상태 RECRUITING
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR-011 (C-CAR-011)

Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR011 (C-CAR011)

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
CGTBiologicstaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes)

Central Nervous System Lymphoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 RECRUITING
AntibodystaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
효능 ORR 9.9%임상시험 6상태 DISCONTINUED
ADCBiologicstaleRochePhase 2

Pola-R- GemOx (Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin, Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx))

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 69.7%임상시험 6상태 RECRUITING
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

anti-CD5 CAR T cells (anti-CD5 CAR T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
ADCBiologicstalePfizerPhase 2

BrECADD (BrECADD)

Hodgkin Lymphoma (Category) · Hodgkin Lymphoma (Category)

#HodgkinLymphomaCategory#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 5상태 RECRUITING
CGTBiologicstaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (CD19-CAR-DNT cells)

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 5상태 ACTIVE
CGTBiologicstaleTakedaPhase 2

CD19-CAR-T2 Cells (CD19-CAR-T2 Cells)

B Cell Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 5상태 ACTIVE
ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Larotrectinib Sulfate (Larotrectinib Sulfate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 60%임상시험 5상태 RECRUITING
CGTBiologicstaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (RJMty19, RJMty19 (CD19-CAR-DNT cells))

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 5상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

SAR3419 (SAR3419)

Diffuse Large B-cell Lymphoma · Acute Lymphocytic Leukaemia

#AcuteLymphocyticLeukaemia#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 5상태 ACTIVE
CGTBiologicstaleShanghai Unicar-Therapy Bio-med…Phase 2

ssCART-19 (ssCART-19)

B Cell Lymphoma · B Cell Lymphoma

#BCellLymphoma#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 5상태 RECRUITING
AntibodystaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 4상태 ACTIVE
CGTBiologicStichting Hemato-Oncologie voor…Phase 2

ARI-0001 (ARI-0001)

NHL; DLBCL - Diffuse Large B Cell Lymphoma · NHL

#NHL#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 4상태 RECRUITING
CGTBiologicThe Affiliated Hospital of Xuzh…Phase 2

Anti-CD56 CAR T (Anti-CD56 CAR T)

Extranodal NK T Cell Lymphoma; NK-Cell Leukemia · Extranodal NK T Cell Lymphoma

#ExtranodalNKTCellLymphoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 4상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab [TECENTRIQ])

Neoplasms · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 33.33%임상시험 4상태 ACTIVE
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

CD7CAR T cells (CD7CAR T cells)

Relapsed/Refractory, High Risk Hematologic Malignancies; T-ALL/Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 4상태 ACTIVE

10 / 31 페이지

← 이전다음 →